Table 2.
Results of follow-up: Women with cancer before or at first (prevalence) control.
| Mutation group | Age group | n |
Observation years |
Cases with prospective cancer | Mean observation time | Annual incidence rate |
|---|---|---|---|---|---|---|
| B1F | <40 | 20 | 78 | 5 | 3.9 | 6.4% |
| 40-59 | 64 | 299 | 7 | 4.7 | 2.3% | |
| 60+ | 16 | 55 | 3 | 3.4 | 5.5% | |
| SUM | 100 | 432 | 15 | 4.3 | 3.5% | |
| B1NF | <40 | 21 | 111 | 2 | 5.3 | 1.8% |
| 40-59 | 38 | 173 | 3 | 4.6 | 1.7% | |
| 60+ | 15 | 42 | 4 | 2.8 | 9.5% | |
| SUM | 74 | 326 | 9 | 4.4 | 2.8% | |
| B2 | <40 | 4 | 19 | 2 | 4.8 | 10.5% |
| 40-59 | 28 | 119 | 3 | 4.3 | 2.5% | |
| 60+ | 15 | 47 | 3 | 3.1 | 6.4% | |
| SUM | 47 | 185 | 8 | 3.9 | 4.3% | |
| ALL | SUM | 221 | 943 | 32 | 4.3 | 3.4% |
B1F: BRCA1 founder mutations (1675delA, 1135insA, 3347delAG, 816delGT)
B1NF: All other BRCA1 mutations
B2: BRCA2 mutations